| __timestamp | Bio-Techne Corporation | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 1213000 |
| Thursday, January 1, 2015 | 119401000 | 3425000 |
| Friday, January 1, 2016 | 140879000 | 6311000 |
| Sunday, January 1, 2017 | 199243000 | 9518000 |
| Monday, January 1, 2018 | 240636000 | 28080000 |
| Tuesday, January 1, 2019 | 264359000 | 36550000 |
| Wednesday, January 1, 2020 | 260583000 | 46125000 |
| Friday, January 1, 2021 | 324951000 | 68486000 |
| Saturday, January 1, 2022 | 372766000 | 92032000 |
| Sunday, January 1, 2023 | 378378000 | 117532000 |
| Monday, January 1, 2024 | 396826000 |
Unleashing insights
In the ever-evolving biotech industry, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Bio-Techne Corporation and Rhythm Pharmaceuticals, Inc., from 2014 to 2023.
Bio-Techne Corporation has shown a consistent upward trend in SG&A expenses, increasing by over 550% from 2014 to 2023. This growth reflects the company's expanding operations and strategic investments. In contrast, Rhythm Pharmaceuticals, Inc. experienced a staggering 9,600% increase in SG&A expenses over the same period, highlighting its aggressive market entry and expansion strategies.
While Bio-Techne's expenses peaked in 2024, Rhythm Pharmaceuticals' data for 2024 is unavailable, indicating potential reporting delays or strategic shifts. These insights provide a window into the financial health and strategic priorities of these biotech giants.
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Bio-Techne Corporation and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Bio-Techne Corporation vs Jazz Pharmaceuticals plc Trends and Insights
Research and Development Investment: Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.